港股生物医药概念股早盘走强，港股医疗、创新药等相关ETF涨超2%

Group 1 - The Hong Kong stock market saw a strong performance in the biopharmaceutical sector, with companies like WuXi Biologics and Crystal International Holdings rising over 5%, and 3SBio increasing by over 4% [1] - The healthcare and innovative drug-related ETFs in Hong Kong also experienced gains of over 2%, indicating positive market sentiment [2] - A report from brokerage firms highlighted that more innovative drug companies are transitioning from the "R&D investment phase" to the "commercialization phase," leading to steady growth in core product sales and some companies achieving profitability [2] Group 2 - Institutional investors, such as public funds, are increasing their allocation to high-quality stocks, which is enhancing market recognition and support for these companies [2] - The focus of the innovative drug market is shifting from broad valuation recovery to the ability of companies to deliver on their fundamentals [2]